These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

465 related items for PubMed ID: 32294172

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Ribotypes and antimicrobial susceptibility profiles of clinical Clostridioides difficile isolates: A multicenter, laboratory-based surveillance in Taiwan, 2019-2021.
    Tsai CS, Lu PL, Lu MC, Hsieh TC, Chen WT, Wang JT, Ko WC.
    J Microbiol Immunol Infect; 2024 Apr; 57(2):320-327. PubMed ID: 38135646
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Reference Susceptibility Testing and Genomic Surveillance of Clostridioides difficile, United States, 2012-17.
    Gargis AS, Karlsson M, Paulick AL, Anderson KF, Adamczyk M, Vlachos N, Kent AG, McAllister G, McKay SL, Halpin AL, Albrecht V, Campbell D, Korhonen LC, Elkins CA, Rasheed JK, Guh AY, McDonald LC, Lutgring JD, Emerging Infections Program C. difficile Infection Working Group.
    Clin Infect Dis; 2023 Mar 04; 76(5):890-896. PubMed ID: 36208202
    [Abstract] [Full Text] [Related]

  • 8. Five-year Pan-European, longitudinal surveillance of Clostridium difficile ribotype prevalence and antimicrobial resistance: the extended ClosER study.
    Freeman J, Vernon J, Pilling S, Morris K, Nicolson S, Shearman S, Clark E, Palacios-Fabrega JA, Wilcox M, Pan-European Longitudinal Surveillance of Antibiotic Resistance among Prevalent Clostridium difficile Ribotypes’ Study Group.
    Eur J Clin Microbiol Infect Dis; 2020 Jan 04; 39(1):169-177. PubMed ID: 31811507
    [Abstract] [Full Text] [Related]

  • 9. Antimicrobial resistance surveillance of Clostridioides difficile in Australia, 2015-18.
    Putsathit P, Hong S, George N, Hemphill C, Huntington PG, Korman TM, Kotsanas D, Lahra M, McDougall R, McGlinchey A, Moore CV, Nimmo GR, Prendergast L, Robson J, Waring L, Wehrhahn MC, Weldhagen GF, Wilson RM, Riley TV, Knight DR.
    J Antimicrob Chemother; 2021 Jun 18; 76(7):1815-1821. PubMed ID: 33895826
    [Abstract] [Full Text] [Related]

  • 10. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
    Debast SB, Bauer MP, Sanders IM, Wilcox MH, Kuijper EJ, ECDIS Study Group.
    J Antimicrob Chemother; 2013 Jun 18; 68(6):1305-11. PubMed ID: 23420839
    [Abstract] [Full Text] [Related]

  • 11. The ClosER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes, 2011-2014.
    Freeman J, Vernon J, Pilling S, Morris K, Nicholson S, Shearman S, Longshaw C, Wilcox MH, Pan-European Longitudinal Surveillance of Antibiotic Resistance among Prevalent Clostridium difficile Ribotypes Study Group.
    Clin Microbiol Infect; 2018 Jul 18; 24(7):724-731. PubMed ID: 29066403
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A nationwide study of molecular epidemiology and antimicrobial susceptibility of Clostridioides difficile in South Korea.
    Byun JH, Kim H, Kim JL, Kim D, Jeong SH, Shin JH, Kim YA, Shin JH, Shin KS, Uh Y.
    Anaerobe; 2019 Dec 18; 60():102106. PubMed ID: 31655214
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Epidemiologic trends in Clostridioides difficile isolate ribotypes in United States from 2011 to 2016.
    Snydman DR, McDermott LA, Jenkins SG, Goldstein EJC, Patel R, Forbes BA, Johnson S, Gerding DN, Thorpe CM, Walk ST.
    Anaerobe; 2020 Jun 18; 63():102185. PubMed ID: 32387171
    [Abstract] [Full Text] [Related]

  • 16. [In Vitro Activities of Antimicrobials Against Toxigenic Clostridioides difficile Isolates Obtained in a University Training and Research Hospital in Turkey].
    Sayın E, Bilgin H, Söyletir G, Ülger Toprak N.
    Mikrobiyol Bul; 2020 Jul 18; 54(3):368-377. PubMed ID: 32755514
    [Abstract] [Full Text] [Related]

  • 17. Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin.
    Snydman DR, McDermott LA, Thorpe CM, Chang J, Wick J, Walk ST, Vickers RJ.
    J Antimicrob Chemother; 2018 Aug 01; 73(8):2078-2084. PubMed ID: 29718329
    [Abstract] [Full Text] [Related]

  • 18. Antimicrobial resistance progression in the United Kingdom: A temporal comparison of Clostridioides difficile antimicrobial susceptibilities.
    Jon J V, Mark H W, Jane F.
    Anaerobe; 2021 Aug 01; 70():102385. PubMed ID: 34048922
    [Abstract] [Full Text] [Related]

  • 19. Characterization of Clostridioides difficile isolates recovered from two Phase 3 surotomycin treatment trials by restriction endonuclease analysis, PCR ribotyping and antimicrobial susceptibilities.
    Cheknis A, Devaris D, Chesnel L, Dale SE, Nary J, Sambol SP, Citron DM, Goering RV, Johnson S.
    J Antimicrob Chemother; 2020 Nov 01; 75(11):3120-3125. PubMed ID: 32747931
    [Abstract] [Full Text] [Related]

  • 20. Diversity of Circulating Clostridioides difficile Ribotypes in Mexico and Susceptibility to Fidaxomicin, Vancomycin, and Metronidazole.
    Martínez-Meléndez A, Tijerina-Rodríguez L, Collins N, Baines SD, Morfin-Otero R, Camacho-Ortíz A, Villarreal-Treviño L, Garza-González E.
    Microb Drug Resist; 2021 Dec 01; 27(12):1672-1676. PubMed ID: 34037477
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.